Crohn Disease: A rational approach to management

Michael F. Picco

Research output: Contribution to journalArticle

Abstract

Crohn disease can involve any part of the digestive tract; it can manifest as inflammatory (diarrhea, abdominal pain, and fever), penetrating (abscess or fistula), or stricturing (recurrent bowel obstruction) disease. Treatment is based on the location and activity of the disease. Mesalamine is recommended to induce and maintain remission in patients with mild to moderate nonpenetrating, nonstricturing disease. Antibiotics may be used as an alternative or adjunct to mesalamine; ciprofloxacin and metronidazole are helpful in fistulizing Crohn disease. For patients with moderate to severe disease, corticosteroids are recommended to induce remission; infliximab is an alternative for those with severe or refractory disease. Remission is then maintained with immunosuppressive therapy, not with corticosteroids. Fistulas are difficult to treat but may respond to antibiotics or azathioprine; however, closure rates are low. Infliximab produces higher closure rates; azathioprine or 6-mercaptopurine should be used to maintain remission in this setting.

Original languageEnglish (US)
Pages (from-to)25-33
Number of pages9
JournalDrug Benefit Trends
Volume14
Issue numberSUPPL. A
StatePublished - 2002

Fingerprint

Crohn Disease
Mesalamine
Azathioprine
Fistula
Adrenal Cortex Hormones
Anti-Bacterial Agents
6-Mercaptopurine
Metronidazole
Immunosuppressive Agents
Ciprofloxacin
Abscess
Abdominal Pain
Gastrointestinal Tract
Diarrhea
Fever
Therapeutics
Infliximab

Keywords

  • Crohn disease
  • Disease management
  • Inflammatory bowel disease
  • Patient care

ASJC Scopus subject areas

  • Leadership and Management
  • Pharmaceutical Science

Cite this

Picco, M. F. (2002). Crohn Disease: A rational approach to management. Drug Benefit Trends, 14(SUPPL. A), 25-33.

Crohn Disease : A rational approach to management. / Picco, Michael F.

In: Drug Benefit Trends, Vol. 14, No. SUPPL. A, 2002, p. 25-33.

Research output: Contribution to journalArticle

Picco, MF 2002, 'Crohn Disease: A rational approach to management', Drug Benefit Trends, vol. 14, no. SUPPL. A, pp. 25-33.
Picco, Michael F. / Crohn Disease : A rational approach to management. In: Drug Benefit Trends. 2002 ; Vol. 14, No. SUPPL. A. pp. 25-33.
@article{3436ee2c83904c5197cfe8919749c90f,
title = "Crohn Disease: A rational approach to management",
abstract = "Crohn disease can involve any part of the digestive tract; it can manifest as inflammatory (diarrhea, abdominal pain, and fever), penetrating (abscess or fistula), or stricturing (recurrent bowel obstruction) disease. Treatment is based on the location and activity of the disease. Mesalamine is recommended to induce and maintain remission in patients with mild to moderate nonpenetrating, nonstricturing disease. Antibiotics may be used as an alternative or adjunct to mesalamine; ciprofloxacin and metronidazole are helpful in fistulizing Crohn disease. For patients with moderate to severe disease, corticosteroids are recommended to induce remission; infliximab is an alternative for those with severe or refractory disease. Remission is then maintained with immunosuppressive therapy, not with corticosteroids. Fistulas are difficult to treat but may respond to antibiotics or azathioprine; however, closure rates are low. Infliximab produces higher closure rates; azathioprine or 6-mercaptopurine should be used to maintain remission in this setting.",
keywords = "Crohn disease, Disease management, Inflammatory bowel disease, Patient care",
author = "Picco, {Michael F.}",
year = "2002",
language = "English (US)",
volume = "14",
pages = "25--33",
journal = "Drug Benefit Trends",
issn = "1080-5826",
publisher = "Cliggott Publishing Co.",
number = "SUPPL. A",

}

TY - JOUR

T1 - Crohn Disease

T2 - A rational approach to management

AU - Picco, Michael F.

PY - 2002

Y1 - 2002

N2 - Crohn disease can involve any part of the digestive tract; it can manifest as inflammatory (diarrhea, abdominal pain, and fever), penetrating (abscess or fistula), or stricturing (recurrent bowel obstruction) disease. Treatment is based on the location and activity of the disease. Mesalamine is recommended to induce and maintain remission in patients with mild to moderate nonpenetrating, nonstricturing disease. Antibiotics may be used as an alternative or adjunct to mesalamine; ciprofloxacin and metronidazole are helpful in fistulizing Crohn disease. For patients with moderate to severe disease, corticosteroids are recommended to induce remission; infliximab is an alternative for those with severe or refractory disease. Remission is then maintained with immunosuppressive therapy, not with corticosteroids. Fistulas are difficult to treat but may respond to antibiotics or azathioprine; however, closure rates are low. Infliximab produces higher closure rates; azathioprine or 6-mercaptopurine should be used to maintain remission in this setting.

AB - Crohn disease can involve any part of the digestive tract; it can manifest as inflammatory (diarrhea, abdominal pain, and fever), penetrating (abscess or fistula), or stricturing (recurrent bowel obstruction) disease. Treatment is based on the location and activity of the disease. Mesalamine is recommended to induce and maintain remission in patients with mild to moderate nonpenetrating, nonstricturing disease. Antibiotics may be used as an alternative or adjunct to mesalamine; ciprofloxacin and metronidazole are helpful in fistulizing Crohn disease. For patients with moderate to severe disease, corticosteroids are recommended to induce remission; infliximab is an alternative for those with severe or refractory disease. Remission is then maintained with immunosuppressive therapy, not with corticosteroids. Fistulas are difficult to treat but may respond to antibiotics or azathioprine; however, closure rates are low. Infliximab produces higher closure rates; azathioprine or 6-mercaptopurine should be used to maintain remission in this setting.

KW - Crohn disease

KW - Disease management

KW - Inflammatory bowel disease

KW - Patient care

UR - http://www.scopus.com/inward/record.url?scp=0036231402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036231402&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0036231402

VL - 14

SP - 25

EP - 33

JO - Drug Benefit Trends

JF - Drug Benefit Trends

SN - 1080-5826

IS - SUPPL. A

ER -